Abstract

In this issue, two cases are described of human African trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense. They occurred recently in European tourists returning from Masai Mara area, Kenya, to Germany and Belgium, respectively [1,2]. These are, to our knowledge, the first two HAT cases described in travellers to Kenya in the last 12 years, while several cases were reported mainly from Tanzania (Serengeti and Tarangire game parks), Zambia, Zimbabwe and Malawi [3]. HAT, also known as sleeping sickness, is caused by a flagellated trypanosome protozoan, which is transmitted by Glossina (tsetse) flies. T. b. gambiense – found in western and central Africa – is transmitted mainly by G. palpalis, which prefers areas of vegetation near rivers and cultivated fields; T. b. rhodesiense – found in eastern and southern Africa – is transmitted predominantly by G. morsitans, which feeds on wild animals in savannah areas, far from human settlements [4]. While humans are the only substantial reservoir of T. b. gambiense, T. b. rhodesiense HAT is a zoonosis and humans occasionally visiting affected areas (usually for hunting or tourism) are accidental hosts. T. b. gambiense HAT is usually characterised by a chronic course of illness, lasting months to years, whereas T. b. rhodesiense HAT causes a more acute and aggressive course, clinically resembling acute septicaemia or severe falciparum malaria, with death occurring within days, weeks or months of the untreated disease. HAT of both forms is characterised by two distinct phases: the early or haemo-lymphatic stage and the late or meningoencephalitic stage, with trypanosome invasion of the central nervous system of patients surviving the early stage [5].

Highlights

  • T. b. gambiense accounts for more than 90% of all reported cases of human African trypanosomiasis (HAT) worldwide, T. b. rhodesiense has been the cause of most imported cases [6]

  • From 2000 to 2010, there were reports of 94 HAT cases diagnosed in non- endemic countries, of which 72% were due to T. b. rhodesiense: of them, 82% were diagnosed at the first stage

  • Cerebrospinal fluid examination is mandatory for the disease staging, even in the absence of neurological signs, because the treatment of the two stages is different [7]: for T. b. rhodesiense HAT, suramin is the drug of choice in the first stage and melarsoprol in the second, while for T. b. gambiense, pentamidine is used in the first stage, a combination of nifurtimox and eflornithine in the second [8]

Read more

Summary

Introduction

T. b. gambiense accounts for more than 90% of all reported cases of HAT worldwide, T. b. rhodesiense has been the cause of most imported cases [6]. Gambiense accounts for more than 90% of all reported cases of HAT worldwide, T. b. Rhodesiense has been the cause of most imported cases [6].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call